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Abstract
Metabolomics, the study of the endogenously synthesized small molecules repertoire
(nonproteinaceous), is of great relevance for establishing a wide view of cell physiology
at specific moments, linking metabolic profiles to phenotypes and genotypes. To better
understand biological systems, such as helminths life cycle, helminthic infection, and
host-parasite interaction, metabolomics studies are crucial. For that, mass spectrometry-
based metabolomics is the most popular strategy. Nontargeted metabolomics allows
researchers to profile entire metabolomes present in cells, tissues, biofluids, or even
samples as complex as stools. Through different mass spectrometric techniques, it is
possible  to  unveil  chemical  markers  for  helminths,  such as  Schistosoma mansoni  (a
trematode) and Ascaris lumbricoides (a nematode), in addition to study mechanisms of
action for different drugs, which targets parasites. Therefore, mass spectrometry allows
designing biochemical pathways that may clarify the processes of parasite life cycle,
helminthic  infection,  and  host-parasite  interaction,  providing  targets  to  further
interference for parasite control or even infection treatment.
Keywords: metabolomics, mass spectrometry, helminths, Ascaris lumbricoides , Schisto‐
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1. Introduction
1.1. Metabolomics and mass spectrometry in biomedical research
The composition of the intracellular environment depends on harmonic and orchestrated
synthesis and interaction of molecules that are essential for cellular survival and healthy life
maintenance [1], and it is true for both eukaryotic and prokaryotic organisms. Eukaryotic cells
present a higher degree of intricacy compared with prokaryotic cells because of the huge
biochemical complexity they present [2]. Helminths represent a pluricellular eukaryotic group
of worms that establish parasitic relationships with humans, which has been registered since
ancient Greek writings [3]. Structurally, helminths are completely different from Homo sapiens,
and it is assured that peculiar metabolic differences exist between these organisms. These
differences enable understanding and studying helminth-human interaction, transmission
routes, and life cycles through molecular studies, the cornerstone in all fields of biomedical
research.
The search for faster, more accurate methodologies that describe the biochemical/pathophy-
siological status of an organism of interest has driven major efforts in biomedical research in
the late years in order to meet the clinical needs for a health community [4]. Bioanalytical
methodologies have then emerged as suitable choices for expeditious approaches that exhibit
great resolution and sensitivity, thus generating the development of more accurate and precise
methodologies. In instrumental bioanalysis, several compounds of interest can be measured
and/or monitored depending on their molecular nature. As there is no “one-size-fits-all”
approach, different molecular classes have demanded the creation of different analytical
strategies in which both comprehensive and specific analyses can be performed. This, there-
fore, has elicited the development of the “omics” strategies, which were subdivided according
to the needs of the researchers. For example, for large and bulky molecules such as proteins,
a wide array of analytical methods compose what is called the proteomics approach, which is
dedicated to study each and every aspect of proteins and their levels, interactions, and
structure in biological systems [5]. The same rationale was then applied for other biological
components, such as genes (genomics) [6], lipids (lipidomics) [7], and small molecules/
metabolites (metabolomics) [8].
Metabolomics can be understood in more detail as the systematic study of small, nonprotein,
both endogenous and exogenous molecules, which represent the end of the entire biological
chain started by gene expression (i.e., phenotype) [9]. Metabolomics studies usually measure
compound classes such as lipids, nucleic acids, amino acids, and glycans, composing a useful
biochemical platform for studying mechanisms of interactions, signalling synthetic pathways
of systems and molecules under different metabolic conditions (e.g., diseases), providing
specific molecules or molecular groups that characterize such conditions: the biomarkers. This
assists in understanding, diagnosing, preventing, and predicting conditions, as well as helps
assessing risks and benefits of pharmacological interventions [10].
Cell metabolism is one of the challenges that have been the driving force of metabolomics over
the years [11]. The efforts on development were to obtain increasingly accurate and well-
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resolved methods, introducing more sophisticated and specific methods such as nuclear
magnetic resonance (NMR) and mass spectrometry (MS) [12]. This made room for a number
of improvements also in data processing and bioinformatics, where multivariate analyses and
big data analytics found a whole new application in resolving and integrating complex
biological matrices and systems [13], giving rise to the four main metabolomics strategies:
metabolic profiling, the identification and quantification of known metabolites that are related
to a specific number of metabolic pathways [14]; metabolic fingerprinting, which comprises
fast-paced analysis to classify a determined sample during high-throughput screenings
(positive/negative or disease/health) [15]; metabolic footprint, which analyses the extracellular
metabolites (i.e., excretion/secretion products) of a given organism [16]; and targeted analysis,
a series of quali-quantitative analyses of any given known metabolite in an orga-nism or a
metabolic pathway [17].
The technical aspects of both NMR and MS place them both as the main tools for metabolomics
studies, especially for their complementary nature. NMR is a spectroscopy-based technique
that relies on the incidence of a magnetic field over the nuclei of atoms with nonzero spin
counts, such as 1H, 13C, and 15N, thus providing accurate structural and quantitative informa-
tion of the metabolic profile under study [18]. There are several advantages associated with
the use of NMR as an analytical tool for metabolomics; as it is not a destructive analysis, i.e.,
it is possible to recover the sample after the analysis, which is useful especially for target
analyses. Moreover, NMR requires little sample preparation and shows great reproducibility,
two desirable features for bioanalyses [19]. In contrast, some disadvantages hamper the wide
distribution of NMR as a routine approach; the high costs associated with instrument main-
tenance and the need for relatively high amounts of the analyte usually turn down NMR as a
high-throughput choice, which finds its best use as a research tool.
Mass spectrometry, on the other hand, despite being sample-destructive, shows great potential
for routine analyses. MS-based bioanalytical systems show superior performance in detection
and quantification limits, easily reaching a working range of nano to picomoles [20]. Relying
on a basic structure of ionization source-mass analyser, MS brings a wide array of combinations
of both, which comprehends virtually any type of sample for metabolomics studies [21], in
addition to the possibility of coupling with chromatographic approaches such as gas chroma-
tography (GC) and high-performance liquid chromatography (HPLC) [22]. Moreover,
structural elucidation strategies with MS are diverse and can be suited according to the needs
and to the instrument available, either with mass accuracy on high-resolution instruments or
with fragmentation profile (MS/MS) in standard devices—or even a combination of the two
[23]. These factors contributed to the popularization of MS among researchers and clinical
experts and have, therefore, provided the basis for great development in this area.
Hence, this chapter will provide a comprehensive overview on the application of metabolomics
analysis and strategies developed for the analyses of helminths, with a particular focus on MS,
reinforcing the great importance of these organisms for general public health. The main aim
is to address recent analytical chemistry methodologies, challenges to overcome and promising
results, expanding possibilities at helminthiasis research, and thus contributing with advances
in the area.
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2. Biochemical characterization of helminthic parasites
2.1. Schistosoma mansoni biochemical characterization
S. mansoni metabolomics studies are conducted to improve the knowledge of disease patho-
logy, to evaluate the behaviour and infectivity of different strains, to elucidate mechanisms of
action, and to evaluate the efficacy of available drugs in addiction to discover biomarkers that
can be applied as diagnostic and drug targets [24].
The main analytical metabolomics approaches are MS and NMR [25], and both of them al-
low performing target or untargeted analysis, which are mostly focused on two classes of
metabo-lites: lipids and oligosaccharides. In case of living organisms, such as parasites, lip-
ids are necessary for cell-cell signalling, for protection from host immunity, for maintenance
of integrity and parasite structure during the life cycle and are also involved in the mecha-
nisms of sexual development, egg production, and cercaria penetration [26–28]. Concerning
oligosaccharides, these molecules are precursors of glycoconjugates such as glycoproteins
and glycolipids that are mainly involved in development of innate and adaptive immune
response in the host, parasite survival, and the chronic infection establishment [29, 30]. Lip-
ids as well glycans may change as long as the parasite develops, thus it is crucial to under-
stand metabolomics patterns according to the different lifecycle stages for each parasite
studied.
2.1.1. Metabolomics approach for S. mansoni lifecycle stages
2.1.1.1. Mature and immature eggs
The main class of lipids present at S. mansoni eggs is glycosphingolipids [31], which are
involved in interactions with the different affected organs, such as gut, lungs, or liver,
facilitating its passage through the tissues [32]. Glycosphingolipids are also reported to be
associated with egg’s high immunogenicity and pathogenicity in different strains [33]. For
example, the granuloma formation occurs by the reaction of host immune response mediated
by parasite glycoconjugates; therefore, the greater abundance of glucosylceramides (GlcCer)
in one strain compared to another, the higher pathogenicity [32, 34]. The same study using
high-resolution mass spectrometry (HRMS) showed that phosphatidic acid (PA), phosphati-
dylserine (PS), phosphatidylethanolamine (PE), triacylglycerol (TG), and diacylglycerol (DG)
are involved in the differentiation of S. mansoni strains [34]. In respect to maturation, immature
and mature eggs present also been differentiated using Matrix-Assisted Laser Desorption/
Ionization—Time of Flight Mass Spectrometry (MALDI-TOF-MS). This research showed that
immature eggs have a common N-glycan profile and are formed predominantly of nonspecific
oligomanoses, while mature eggs have highly complex and fucosylated N-glycans [30].
Therefore, lipid molecules in eggs show differences according to maturation phases and
diverge between distinct strains.
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2.1.1.2. Miracidium
This is about a free-living and motile form that penetrates in Biomphalaria sp. snails, the
intermediate host of the S. masoni lifecycle. Different strains were analyzed by HRMS, and the
results showed the possibility to differentiate two strains of miracidium by identifying
different lipids: triacylglycerol (TG), phosphatidylserine (PS), phosphatidic acid (PA), phos-
phatidylinositol-ceramide (PI-Cer), and dodecanoid acid (DA). The most interesting lipid
among them is the last compound, reported to be responsible for facilitating the penetration
of miracidium in snails [27]. Considering glycolipid studies through MALDI-TOF-MS analysis,
miracidium glycolipids have been almost devoid of LeX- or LN-motifs, what is coherent with
previous data that showed snail infection is apparently independent of LeX-motifs, but LDN-
motifs are fairly present in miracidium and snail. Observing that the parasite presented the
same spectra compared to the intermediate host, miracidium appear to develop a snail-
compatible glycosylation pattern [30]. These molecular studies show lipid variability and/or
similarity among different lifecycle stages, opening opportunities to better understand
interactions between parasite and host/intermediate host or to interfere at metabolic pathways,
as long as we know where and how [30, 35].
2.1.1.3. Cercaria
Cercaria, the final larval stage of S. mansoni lifecycle, produces secretions that facilitate skin
penetration. These fluids are reported to be weak immunogenic and composed of glucopro-
teins and glycolipids. Mass spectrometry approaches demonstrate the predominance of
ceramides-linked glucose and/or galactose with fucose and xylose cores at cercaria secretions
[30, 33, 36]. Another study also determined the cercaria differentiation between two S. mansoni
strains by HRMS. The lipids TG, DG, PE, PA, and phosphatidylglycerol (PG) were reported to
be responsible for this discrimination [27].
2.1.1.4. Adults
The tegument surface structure of S. mansoni adult worms is crucial for parasite survival and
modulation of host immune response. This structure is syncytial and is covered by two closely
apposed lipid bilayers, one of them is an inner plasma membrane and the other an outer
membranocalyx complex [28, 37]. Mass spectrometry studies conducted with tegument and
whole worm demonstrate an enrichment of the phosphatidylcholine (PC) and PS of tegumen-
tal compositions, but this phenomena does not occur with PE and PI, which presents the same
composition for the two worm fractions. The tegumental membranes are also enriched with
lysophospholipids, mainly lyso-PS and lyso-PE containing eicosanoic acid (20:1) [28].
As regards glycans, their composition dramatically changes during the development stages.
Comparing with early life-stages, adult worms present smaller ratio between complex type-
glycans and oligomannosidic glycans and the antigenic core composed by xylose is undetect-
able [30].
Mass spectrometry imaging (MSI) enables the study of spatial distribution of biomarkers.
Ferreira and co-workers (2014) used MALDI-MSI to image two different S. mansoni strains.
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Figure 1 shows the sum of all ions obtained by the imaging analysis where it is possible to
detect both male and female worms’ bodies. The spectra obtained from the single worms were
compared with the pair and enabled the election of specific ions for male and female worms
[34].
Figure 1. Representative fingerprinting of Schistosoma mansoni adult couple worms. The imaging represents a sum of
all ions within mass range 600–2000 m/z. (A) Picture of worms analyzed. Gynaecophoric channel in male’s body (clear)
holding female’s body (dark). (B) Worms’ image generated by MALDI-MSI instrument. Illustrative picture of finger-
printing analysis. (C) Representative fingerprinting (total ion current) spectra. Positive ion mode.
The same study determined the ions responsible for the differentiation of male and female
worms of two different strains and their localization in a worm body. The fingerprint of each
worm was submitted to Principal Component Analysis (PCA), and the groups of strains are
discriminated, enabling the selection of chemical markers for each group. New MS/MS
imaging was performed and the distribution of the parental ions selected by PCA can be seen
in Figures 2 and 3.
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Figure 2 shows the male and female image of BH strain obtained by MALDI-MSI analysis.
Female worm presents the predominance of PC (823, 665 and 761 m/z) and PG (764 m/z)
distributed to reproductive and digestive systems. Male worm presents diacylcglycerol (DAG)
(635 and 651 m/z) in ventral sucker and gynaecophoric channel, triacylglycerol (TAG) (846 and
886 m/z) in ventral sucker and reproductive system, phosphatidic acid (PA) (675 m/z) in ventral
sucker and gynaecophoric channel, PI (862 m/z) in reproductive and digestive systems and
ventral sucker, and finally, PC (887 m/z) in reproductive system and ventral sucker.
Figure 2. Adult worms generated by MS, selected using each of the parent ions in MS/MS mode. Images were acquired
as one run for each m/z. Female and male BH strain (FBH and MBH, respectively). Pos, posterior portion; Ant, anterior
portion; R, reproductive system; D, digestive system; VS, ventral sucker; OS, oral sucker; and GC, gynaecophoric chan-
nel.
Figure 3. Adult worm images generated by MS, selected using each of the parent ions in MS/MS mode. Images were
acquired as one run for each m/z. Female and male SE strain (FSE and MSE, respectively). Pos, posterior portion; Ant,
anterior portion; R, reproductive system; VS, ventral sucker; and OS, oral sucker.
Figure 3 shows male and female image of SE strain obtained by MALDI-MSI analysis. Female
worm presents the predominance of PI (623 m/z) and DAG (606 m/z) distributed mainly in
tegument while male worm presents TAG (786 and 850 m/z) and PC (825 m/z) in ventral and
oral suckers and reproductive system.
Ferreira and coworkers (2014) demonstrate that it is possible to determine spatial distribution
of biomarkers for parasites and also show that more studies are necessary to understand the
function of each chemical markers according to the organs they are located, searching for its
influence through pathogenicity of different strains. Furthermore, a new platform of study
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putting together metabolomic and mass spectrometry techniques was proposed and was
named as Parasitomics.
2.2. Ascaris lumbricoides and chemical markers at moulting process
According to Pullan and coworkers [38] and CDC [39], it is estimated that 800–1200 million
people are infected with Ascaris lumbricoides worldwide and more than 60,000 deaths occur
annually because of Ascariasis (spectrum of disease caused by Ascaris lumbricoides infection).
World Health Organization has applied some strategies for disease burden control, such as
deworming programmes [40]. In case of soil-transmitted helminthiasis, the main public health
strategy is the mass drug administration (MDA), which consists of anthelmintic drug treatment
regularly provided to risk population, mainly school-aged children [40, 41]. Despite the great
efforts, approximately 30% of children are really receiving the anthelmintic treatment in the
whole world [42]. Besides the absence of total coverage of MDA worldwide, there is still
another issue to pay attention, the development of anthelmintic drug resistance [43–45].
Taking into account all of these issues cited above, beyond the disability-adjusted life years
(DALYs) in consequence of morbidity and mortality indexes, it is necessary to better compre-
hend and to deal with helminthic parasites, such as Ascaris lumbricoides, in a different point of
view. It is urgent to evaluate and discover different and better ways to control and eliminate
it. Therefore, to outline strategies that are suitable for its life cycle could bring light to mana-
gement of helminthiasis. Since part of the development of A. lumbricoides happens in the soil
[46, 47], it is therefore reasonable to consider that breaking the life cycle during the phases in
the environment would be a valuable attempt in containing the infection in endemic areas [48].
Molecular detailed analysis of the diverse A. lumbricoides forms may elucidate new targets for
parasite control. Metabolic fingerprinting using mass spectrometry has been widely employed,
targeting parasite-related metabolites [34, 49, 50]. The trend of establishing target molecules
and linking them with important metabolic pathways in the parasite life cycle broadens the
knowledge in the field, generating a platform that will assist in better knowledge on their
biology, elucidation of survival mechanisms, pharmacodynamics, diagnostic methodologies,
development of pharmaceutical products to eradicate these diseases, whether in soil or living
hosts, etc. [50, 51].
Melo and coworkers aimed to characterize, in a simple way, the larval development stages of
A. lumbricoides (the traditional human ascariasis agent) by metabolic fingerprinting using
HRMS from stool samples [52]. The molecular elucidation in different life stages presents a
huge potential for application in parasite infection control, breaking the life cycle and reducing
infection and re-infection of exposed human beings, mainly at endemic zones.
From Ascaris lumbricoides specimens, it is possible to separate different development larval
stages using optical microscopy. Melo’s researchers group analyzed stool samples collected
from school-aged children at Brazil. Nonembryonated and embryonated eggs, containing L1
and L3 larvae, could be separated from stool pool. L2 stage larvae were excluded from samples
because it is an overlapping period between the end of L1 and the beginning of L3, what makes
it difficult to identify and isolate. Considering the high sensitivity of mass spectrometer
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analyser, it was necessary to clean as much as possible this complex sample, what favors the
real identification of significant molecules [52].
For molecular screening like this, starting from a complex sample, it is necessary to do a
multivariate statistical analysis for correct identification of targets. For the present study,
Principal Component Analysis (PCA) was chosen to statistically determine relevant groups of
ions, what led to identification of the correspondent molecular biomarkers for each develop-
ment stage under analysis. From the elected ions by PCA, it was possible to achieve the most
suitable chemical markers through metabolome databases analysis, along with a good
literature review. ESI-HRMS analysis of Ascaris lumbricoides specimens showed different
spectral signals among the egg, L1 and L3, and PCA statistical analysis elected distinct chemical
markers for each structure/larval stage.
2.2.1. Metabolomics approach for A. lumbricoides lifecycle stages
2.2.1.1. Eggs
Considering eggs analysis, it was possible to identify five biomarkers: hexadecenal (515 m/z),
21-Methyl-8Z-pentatriacontene (522 m/z), 3,7,11,15-Tetramethyl tetratriacontane (565 m/z),
and two unsaturated fatty acids, corresponding to 537 m/z. The phospholipid hexadecenal
may probably be a by-product of sphingosine-1-phosphate (S1P) degradation. Hexadecenal is
associated with cytoskeleton reorganization, JNK-dependent apoptosis, and proliferation
signalling pathways. Since the analyzed eggs were under embryogenesis, JNK pathway may
favor cell proliferation and embryo development [53–55]. Taking into account that hexadecenal
appears only in the mass spectra of eggs, it may be acting in signalling during embryonic
development process according to weather conditions, food availability and population,
among others [56].
Two other signals elected by PCA, 21-Methyl-8Z-pentatriacontene (522 m/z) and 3,7,11,15-
Tetramethyl Tetratriacontane (565 m/z), correspond to signalling molecules in insects, al-
though their function is not clear yet. There were still two unsaturated fatty acids elected for
eggs (537 m/z) that, based at their carbon chain, it is supposed they have a role at preventing
water loss, considering that fertilized eggs are constantly at high risk of dehydration in the soil
[57, 58].
2.2.1.2. L1 moulting stage
Considering biomarkers statistically elected for L1, a total of four molecules were selected. One
of them, 2-deoxyecdysone-22-phosphate (563 m/z), is a steroid hormone source found during
insects embryogenesis. These steroid hormones, commonly called ecdysones, are associated
with control of development in insects and nematodes, processes called moulting [59]. Taking
into account that ecdysone synthesis depends on cholesterol [60], it is necessary for the
nematode to absorb it. Therefore, it could explain the election of cholesteryl ester (CE) as a
second biomarker at L1 stage [61, 62].
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The lipid composition may vary according to environmental conditions and parasite life stage.
Elected as L1 biomarker, cardiolipins are examples of molecules present at the inner mito-
chondrial membranes [63], whose constitution may vary to adapt to different aeration
conditions. Considering that the development of A. lumbricoides occurs through different life
stages with distinct air availability [64], it is coherent that oxidative stress conditions interfere
with mitochondrial lipid composition. In addition to cardiolipins, sphingolipids (SPL) were
one of the chemical markers elected at L1 stage. SPL is an important class of lipids and may
be modified according to the cycle life stage, just similarly as it happens with insects’ devel-
opment [65].
2.2.1.3. L3 moulting stage
The last larval stage studied at Melo’s work was L3, and one of the possible markers was
Dimethylheptatriacontane. It is a signalling molecule involved with sexual communication
between arthropods, better known as pheromone [66]. Considering nematodes and arthropods
are closely related, some hypothesis were raised about its function at A. lumbricoides L3: (i) it
could play the same role as in arthropods; (ii) to stimulate sexual differentiation during parasite
development [67]; (iii) to act as a “messenger” during development according to environmen-
tal conditions [56]. Depending on the life stage, this signalling molecule may present more than
one function, but the exact role of dimethylheptatriacontane at nematodes is still to be unveiled.
Considering all biomarkers elected for different lifecycle stages for Ascaris lumbricoides, it is
possible to observe that there is a whole metabolic parasite world to discover and establish
connections. Therefore, it is too important to keep looking for new biochemical pathways that
explain parasite similarities, survival, development, host invasiveness, and immunogenicity.
Only the entire knowledge will answer the unsolved questions and allow human interference
to improve health conditions and social development.
3. Searching for drug targets at helminthiasis—Praziquantel and
Schistosoma mansoni chemical targets
It is estimated that about 2 billion people in the world, especially the inhabitants of developing
regions such as sub-Saharan Africa, East Africa, Asia, and the Americas are infected with one
or more helminths, making parasitic diseases very expensive for public health [68–70]. The
drugs used until now to treat these diseases are far from ideal, and many of them were
introduced decades ago [71, 72]. Most of these drugs are related to serious adverse effects,
which supports the low adherence to treatment by patients. Moreover, these drugs have
limited efficacy and can have their activity paralyzed due to the phenomenon of drug resist-
ance [72, 73]. The treatment of such parasitic diseases is mainly related to two factors: sanitation
and health education, which when combined with the use of anthelmintic drugs promote the
success of treatment and avoids occurrence of new cases [73, 74].
Ascariasis is a parasitic disease caused by infection with the nematode Ascaris lumbricoides,
which is one of the soil-transmitted helminthiasis that head the list of the so-called “Neglected
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Diseases” [69, 75]. This parasitic disease has been associated with intestinal pathology,
respiratory symptoms, and malnutrition in children from endemic areas [76, 77]. The indicated
treatment for Ascariasis is based at anti-helminthic drugs against A. lumbricoides, which have
been found to be safe and effective. Single oral doses of Albendazole, Mebendazole, and
Pyrantel pamoate have demonstrated high cure rates against this parasite [69].
Albendazole and Mebendazole are Benzimidazole-based compounds, which are the most
widely used anthelmintics until now [75]. These medicines are known as antimicrotubule
agents due to their therapeutic effect by relating with the capacity of binding to free β-tubulin.
This attachment inhibits tubulin polymerization and disrupts microtubules, which loses
structure and function, leading the organism to death [78, 79]. The selective toxicity of these
agents results because Benzimidazoles bind parasite β-tubulin with much higher affinity than
the mammalian protein [80]. However, there are evidences of drug resistance due to existence
of cases where loss of efficacy has been reported after administration of a single dose [44, 81].
Schistosomiasis is also part of the list of “Neglected Diseases” and is responsible for infecting
more than 200 million people in tropical and subtropical regions of the world, especially in
sub-Saharan Africa [82, 83]. Introduced in the early 1980, Praziquantel (PZQ) is the drug of
choice in the treatment of schistosomiasis. The detailed molecular mechanism of action of PZQ
has not yet been fully explained, but it is related with tegumental damage and paralytic
muscular contraction of parasites via influx of Ca2+ across the tegument [74, 84].
PZQ is a safe anthelmintic, but cases of drug resistance are already known, such as reported
for ascariasis. The first field report came from a new and epidemic focus in northern Senegal
[85]. Many infections that persisted after treatment and were not detected by the usual
diagnostic methods (with eggs per gram below the detection limit of the coprological techni-
ques) required repeated or very sensitive examinations [86, 87]. Thus, the recommended doses
of medicine for schistosomiasis should be considered subcurative [88], and it is safe to assume
that in schistosome populations, some individual parasites are tolerant to the drug, at least at
the usual dosages [73].
The phenomenon of anthelmintic resistance is a genetic modification that can be defined as a
state of insensitivity or decreased sensitivity to the effect of a determined drug concentration,
conferring a number of parasites of a given population the capacity to survive the pharmaco-
logical effect of recommended therapeutic doses of an anthelmintic [75]. In veterinary practice,
frequent treatment of closed populations has led to a serious problem of anthelmintic drug
resistance, which is now largely irreversible [73]. Thus, it is urgently needed to search and
develop sensitive tools for early detection and monitoring of drug resistance, as well as new
anthelmintic evaluation of drug combinations for parasite control.
Drug discovery is an iterative process where different strategies can be applied. Usually, it can
be divided into several distinct stages, starting with target identification and validation,
proceeding to assay development and screening (whole cell or target molecular basis) and
ending with hits identification. Thenceforward, it is necessary to synthesize and evaluate
analogues to verify the structure-activity relationships and identify the elected hit; to optimize
Mass Spectrometry and Metabolomics—New Approaches for Helminth Biochemical Studies
http://dx.doi.org/10.5772/65040
29
its structure, interactive medicinal chemistry is used, and finally, it is done on all preclinical
development before the clinical evaluation [71].
Target-based drug discovery starts with the identification and elucidation of the function of a
potential therapeutic drug target and understanding its role in the disease process. Drug
targets are, basically, molecular structures that will undergo a specific interaction with
chemicals (drugs), which are administered to treat or diagnose a disease. Most of the times,
drug targets are enzymes or proteins involved in biological activity, which are produced by
expression of active genes in a cell [70]. Furthermore, it is interesting to develop drugs whose
targets include biochemical pathways, such as cellular physiological process or cell signalling
molecules. For example, it has been reported as an inhibitor of programmed cell death pathway
(apoptosis) to be a potential small molecule acting on a caspase to control schistosomiasis
caused by S. japonicum [89]. Therefore, metabolic pathways can also be explored as therapeutic
targets, where there should be a clear understanding of anthelmintics mechanisms of action
operating in helminth parasites [70].
For exploratory studies as cited above, metabolomics is a very powerful tool to connect parasite
metabolism and its interaction with the drug of choice. To better understand some of these
mechanisms, chromatographic techniques combined with MS have been employed for
chemical characterization of adult schistosomes and PZQ metabolites in the host [90, 91]. In a
study from 2015, researchers used MS Imaging (MALDI-MSI) to better understand some of
the mechanisms of interaction between PZQ and schistosomes. The researchers were able to
characterize both sexes of S. mansoni adult worms (BH strain) treated with PZQ and identified
the spatial distribution of chemical markers. In addition to tegumental damage, PZQ signifi-
cantly changed the metabolic profile of both sexes of S. mansoni [49]. These data are supported
by a recent work where tegumental damage of schistosomes under PZQ exposure was
demonstrated through scanning electronic microscopy and optical microscopy [92]. These
findings could be helpful for understanding possible targets and pathways of this anti-
schistosomal drug and demonstrates the versatility and potential use of mass spectrometry-
based metabolomics for identification of drug targets.
4. Conclusions
New tools are now available for biomedical research, and mass spectrometry techniques are
among them. In “omics” research, huge opportunities are rising and enable to understand
mechanistic basis for biological differences. For example, the absence of an enzyme in deter-
mined disease might be compared with healthy samples, unveiling significant molecular
differences that clarify the mechanisms of action associated with a genetic failure. This new
approach for biological systems allows the correlation between genotype and phenotype
aspects, which is a complex process nowadays. Metabolomics studies are now giving the
molecular profile of health or disease just like a “snapshot” of cell physiology. It is up to us
scientists to establish the right and coherent correlations between metabolic patterns and
biological alterations.
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Although helminthiasis still consists of a neglected disease, concerning all the discussed topics,
it is possible to keep looking for new strategies that help to control and treat these infections.
The groups of molecules identified by metabolomics approaches, exemplified as MS, might be
tested and correlated with the proposed hypothesis, and then it may be possible to finally
understand the parasites metabolism. In this way, it will be possible to comprehend the
mechanisms of all different lifecycle stages, expanding the field of action for parasite control.
In addition, metabolomics can bring light to the designing of new therapeutic drugs, highly
effective and specific, reducing collateral effects and drug resistance.
Therefore, mass spectrometry and metabolomics show huge potential as new tools to unveil
metabolism of different biological systems, including helminths. The more scientists unveil
about metabolism of parasites and parasite-host interactions, the greater the chances of
improving public health aiming a better future.
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